Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  El Serafi, Ibrahim ^a   Afsharian, Parvaneh ^a,d   Moshfegh, Ali ^a   Hassan, Moustapha ^a,b   Terelius, Ylva ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Medivir AB ^*  (Sweden)

^d ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 REDUCTASE; FLUDARABINE; MESSENGER RNA; THYMOCYTE ANTIBODY; CYTOCHROME P450; POR PROTEIN, HUMAN; PRODRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; EX VIVO STUDY; GENE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; MICROSOME; MIDDLE AGED; NONHODGKIN LYMPHOMA; POR GENE; PROTEIN EXPRESSION; SCHOOL CHILD; T CELL LYMPHOMA; UPREGULATION; WHOLE BODY RADIATION; YOUNG ADULT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASES; METABOLISM;

ADOLESCENT; ADULT; CHILD; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICROSOMES; MIDDLE AGED; PRODRUGS; YOUNG ADULT;

EID: 84952690609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141979     Document Type: Article

References (43)

1. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, et al. (2008) Clinical applications of bloodderived and marrow-derived stem cells for nonmalignant diseases. JAMA 299: 925-936. doi: 10.1001/jama.299.8.925 PMID: 18314435
2. Reynolds M and McCann SR (1989) A comparison between regimens containing chemotherapy alone (busulfan and cyclophosphamide) and chemotherapy (V. RAPID) plus total body irradiation on marrow engraftment following allogeneic bone marrow transplantation. Eur J Haematol 43: 314-320. PMID: 2684682
3. Binotto G, Trentin L and Semenzato G (2003) Ifosfamide and cyclophosphamide: effects on immunosurveillance. Oncology 65: 17-20. PMID: 14586142
4. Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301-355. PMID: 3290910
5. Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, et al. (2004) Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos 32: 1341-1344. PMID: 15383491
6. Chang TK, Weber GF, Crespi CL and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637. PMID: 8242617
7. Ren S, Yang JS, Kalhorn TF and Slattery JT (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57: 4229-4235. PMID: 9331082
8. Xie H, Griskevicius L, Stahle L, Hassan Z, Yasar U, Rane A, et al. (2006) Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 27: 54-61. PMID: 16183265
9. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15: 861-873. PMID: 16272958
10. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al. (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIVinfected patients. Pharmacogenet Genomics 15: 1-5. PMID: 15864119
11. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, et al. (2004) Homozygous CYP2B6 ∗6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319: 1322-1326. PMID: 15194512
12. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11: 399-415. PMID: 11470993
13. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, et al. (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14: 225-238. PMID: 15083067
14. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y and Kamataki T (2001) A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281: 1256-1260. PMID: 11243870
15. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, et al. (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3: 53-61. PMID: 12629583
16. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, et al. (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311: 34-43. PMID: 15190123
17. Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, et al. (2012) Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. Eur J Clin Pharmacol 68: 389-395. doi: 10.1007/s00228-011-1134-0 PMID: 22012257
18. Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, et al. (2012) Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab Dispos 40: 54-63. doi: 10.1124/dmd.111.039347 PMID: 21976622
19. Fernandes BJ, Silva Cde M, Andrade JM, Matthes Ado C, Coelho EB and Lanchote VL (2011) Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. Cancer Chemother Pharmacol 68: 897-904. doi: 10.1007/s00280-011-1554-7 PMID: 21290248
20. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, et al. (2010) Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 16: 6169-6176. doi: 10.1158/1078-0432.CCR-10-0281 PMID: 21169260
21. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP and Hollenberg PF (2011) Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J Pharmacol Exp Ther 338: 803-809. doi: 10.1124/jpet.111.183111 PMID: 21659470
22. Wang SL, Han JF, He XY, Wang XR and Hong JY (2007) Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug Metab Dispos 35: 176-179. PMID: 17062779
23. Pandey AV, Fluck CE and Mullis PE (2010) Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochem Biophys Res Commun 400: 374-378. doi: 10.1016/j.bbrc.2010.08.072 PMID: 20732302
24. Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. (2004) Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36: 228-230. PMID: 14758361
25. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, et al. (2005) Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76: 729-749. PMID: 15793702
26. Merla G, Howald C, Henrichsen CN, Lyle R, Wyss C, Zabot MT, et al. (2006) Submicroscopic deletion in patients with Williams-Beuren syndrome influences expression levels of the nonhemizygous flanking genes. Am J Hum Genet 79: 332-341. PMID: 16826523
27. Agrawal V, Huang N and Miller WL (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18: 569-576. doi: 10.1097/FPC.0b013e32830054ac PMID: 18551037
28. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, et al. (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 20: 677-686. doi: 10.1097/FPC.0b013e32833f4f9b PMID: 20940534
29. Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL and Tracy TS (2012) Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 22: 590-597. doi: 10.1097/FPC.0b013e3283544062 PMID: 22547083
30. Zhang JJ, Zhang H, Ding XL, Ma S and Miao LY (2012) Effect of the P450 oxidoreductase ∗28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur J Clin Pharmacol.
31. Chen X, Pan LQ, Naranmandura H, Zeng S and Chen SQ (2012) Influence of Various Polymorphic Variants of Cytochrome P450 Oxidoreductase (POR) on Drug Metabolic Activity of CYP3A4 and CYP2B6. Plos One 7.
32. Wortham M, Czerwinski M, He L, Parkinson A and Wan YJY (2007) Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metabolism and Disposition 35: 1700-1710. PMID: 17576804
33. de Jonge H, Metalidis C, Naesens M, Lambrechts D and Kuypers DR (2011) The P450 oxidoreductase ∗28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12: 1281-1291. doi: 10.2217/pgs.11.77 PMID: 21770725
34. Gordon MY, Goldman JM and Gordon-Smith EC (1985) 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 9: 1017-1021. PMID: 4046632
35. Singer CR and Linch DC (1987) Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging. Leuk Res 11: 953-959. PMID: 3320579
36. Afsharian P, Mollgard L, Hassan Z, Xie H, Kimby E and Hassan M (2005) The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. Eur J Haematol 75: 206-211. PMID: 16104876
37. Griskevicius L, Meurling L and Hassan M (2002) Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma. Ther Drug Monit 24: 405-409. PMID: 12021633
38. El-Serafi I, Abedi-Valugerdi M, Potacova Z, Afsharian P, Mattsson J, Moshfegh A, et al. (2014) Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. Plos One 9: e86619. doi: 10.1371/journal.pone.0086619 PMID: 24466173
39. Xie HJ, Broberg U, Griskevicius L, Lundgren S, Carlens S, Meurling L, et al. (2003) Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant 31: 197-203. PMID: 12621481
40. Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, Nakamura H, et al. (2011) Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 39: 2045-2048. doi: 10.1124/dmd.111.039586 PMID: 21821736
41. Hart SN and Zhong XB (2008) P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4: 439-452. doi: 10.1517/17425255.4.4.439 PMID: 18433346
42. Rodriguez G (1994) Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma. Invest New Drugs 12: 75-92. PMID: 7532163
43. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. (2009) Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 10: 579-599. doi: 10.2217/pgs.09.7 PMID: 19374516